Endo Pharmaceuticals asked to remove Opana ER from the market
by Press Release from Outbreak News Today on (#2SGJM)
On Thursday, the U.S. Food and Drug Administration requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market. After careful consideration, the agency is seeking removal based on its concern that the benefits of the drug may no longer outweigh its risks. This is the first time the ["]
The post Endo Pharmaceuticals asked to remove Opana ER from the market appeared first on Outbreak News Today.